Tirzepatide 30mg dosage: correcting a common misconception

The misconception: 30mg tirzepatide as a weight-loss dose

Search for "tirzepatide dosage 30mg" and you will find forum threads, peptide supplier pages and social-media posts treating 30mg as if it were the next rung on the Mounjaro ladder. It is not. Mounjaro, the only tirzepatide product licensed in the UK for weight management and type 2 diabetes, comes in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg. That list ends at 15mg. The NHS patient page on tirzepatide confirms the approved dose range, and the medicine's Summary of Product Characteristics (the regulatory document every licensed medicine carries) does not include a 30mg strength.

So where does the number come from? Mostly from the research-peptide market. Some suppliers sell unlicensed tirzepatide-sequence compounds in vials, occasionally at higher concentrations, under descriptions like "tirzepatide 30mg." These are not Mounjaro. They bypass the licensed supply chain, have not gone through the same manufacturing standards, and in many cases are sold without any clinical assessment whatsoever. The MHRA has warned repeatedly about counterfeit and unlicensed weight-loss products sold online; fake pens have been found to contain harmful substances including insulin. If you are researching a dose that sits outside the 2.5–15mg range, the safest thing to do is treat that as a red flag rather than a reference point.

The distinction matters clinically as well as legally. A medicine's licensed dose range is not an arbitrary ceiling, it reflects the evidence gathered during clinical trials and reviewed by regulators. Going beyond it means going beyond what is known about safety and efficacy in humans under controlled conditions.

What the actual tirzepatide dose schedule involves

Tirzepatide treatment in the UK starts at 2.5mg. That first pen is not intended to produce significant weight loss, its job is to let your system adjust to the medicine before the dose moves. Most people then step up in 2.5mg increments roughly every four weeks, guided by how they're tolerating each level. A prescriber may keep someone at an intermediate dose (say 5mg or 10mg) if that's working well or if side effects make a faster increase unwise.

The maintenance dose for most people ends up somewhere between 5mg and 15mg. SURMOUNT-1, the pivotal trial published in the New England Journal of Medicine, tested 5mg, 10mg and 15mg maintenance doses over 72 weeks and found average weight reductions of around 15%, 19.5% and 20–21% respectively. These figures come from thousands of participants in a controlled trial setting and are the numbers behind NICE's recommendation of tirzepatide for eligible adults, not a ceiling waiting to be pushed higher by choosing a bigger dose from an unlicensed source. You can read the full eligibility criteria NICE has set out in Technology Appraisal TA1026.

One practical habit worth building: before your dose increases, check the expiry date on your current pen and confirm the next strength is what your prescriber actually requested. It takes under a minute and prevents mix-ups that can happen when pharmacies batch different strengths together.

Why dose increases are paced rather than accelerated

The gradual titration schedule exists because tirzepatide's most common side effects (nausea, loose stools, indigestion) are dose-dependent. They tend to be most noticeable in the first week or two after a dose step, and stepping up too quickly means stacking that discomfort before the previous level has settled. A prescriber holding someone at 5mg longer than the minimum interval is not being cautious for the sake of it; they are protecting the person's ability to stay on treatment at all.

The same logic applies in reverse. Searching for a higher dose than licensed (whether framed as "tirzepatide 30mg" or anything else) typically reflects frustration that weight loss has slowed. That plateau is real and worth discussing, but the clinical response is almost never to dramatically exceed the licensed ceiling. It is to review the full picture: diet, activity, sleep, other medicines, and whether the current dose is genuinely the highest the person can tolerate. Our clinical team works through exactly that kind of review with patients who feel their treatment has stalled.

If you are curious about how the licensed dose range compares across strengths, the tirzepatide dosage overview covers each step in detail. For context on the broader treatment landscape (including how Mounjaro fits alongside other licensed options) the weight-loss treatments overview is a useful starting point.

Private access to licensed tirzepatide in the UK

Mounjaro is available privately through GPhC-registered online pharmacies, including through nume, for adults who meet the licensed criteria and are assessed as suitable by a prescriber. The licensed criteria for private prescribing broadly mirror the clinical licence: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. BMI alone does not guarantee approval; the prescriber looks at the full picture.

What this route does not involve is choosing your own dose in advance. The prescriber sets the starting point, reviews your response, and adjusts from there, all within the 2.5–15mg licensed range. Privately, there is no waiting list of the kind that applies on the NHS, and the cost context for treatment at each dose level is set out on the Mounjaro pricing page. If you are ready to find out whether treatment is appropriate for you, a free consultation with a GPhC-registered prescriber is the right next step.